4.7 Article

Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study

Journal

GASTROINTESTINAL ENDOSCOPY
Volume 76, Issue 4, Pages 756-760

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.gie.2012.05.023

Keywords

-

Ask authors/readers for more resources

Background: There is no satisfactory treatment for nonalcoholic steatohepatitis (NASH). The Bioenterics intragastric balloon (BIB) can be an effective treatment for weight reduction in obese patients. Objective: We evaluated the efficacy of the BIB in improving the histology of NASH in obese patients. Design: Randomized, controlled study. Setting: University hospital. Patients: Obese patients with body mass indexes (BMI) >= 27 kg/m(2) and who had histologic evidence of NASH were recruited. Intervention: Patients were randomly assigned to a step 1 American Heart Association (AHA) diet plus exercise and BIB placement or step 1 AHA diet plus exercise and sham BIB placement for a period of 6 months. Main Outcome Measurements: Liver histology was the primary outcome measure recorded before and after treatment. Results: A total of 18 patients completed the study. Baseline characteristics of the BIB and sham groups were similar. At 6 months, a significant reduction in the mean BMI was seen in the BIB group (1.52 vs 0.8; P = .0008). The median nonalcoholic fatty liver disease activity scores at the end of treatment were significantly lower in the BIB-treated compared with the sham-treated groups (2 [0.75] vs 4 [2.25]; P = .03). There was a trend toward improvement in the median steatosis scores (1 [0.75] vs 1 [1]; P = .075). There was no change in the median loblular inflammation, hepatocellular ballooning, or fibrosis scores in both groups after treatment. Limitations: Pilot study with small numbers and short duration. Conclusion: Results from this pilot study demonstrated that addition of BIB for 6 months provided a greater loss of BMI and improvement in 2 of 5 histologic parameters of nonalcoholic fatty liver disease. A longer study with larger numbers will be required to prove whether or not the therapy is meaningful in the treatment of NASH. (Gastrointest Endosc 2012;76:756-60.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available